Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has appointed Milan Zdravkovic its new head of research and development (R&D).
He joins from Danish diabetes giant Novo Nordisk (NOV:N), where Dr Zdravkovic has spent 18 years working within R&D, gaining experience spanning from early-stage development to post-approval life-cycle management.
Dr Zdravkovic has worked in a range of therapeutic areas including diabetes, growth hormone deficiency and immunology. His most recent role was as corporate vice president, obesity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze